All In Biotech

Drug Trial Radar · NCT03000946

Prevention of Postoperative Pancreatic Fistula by Somatostatin

Prevention of Postoperative Pancreatic Fistula by SOMATOSTATIN Compared to OCTREOTIDE: Prospective, Randomized, Controlled Study

Last checked: Nov 19, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 655 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

655

Actual

Start

May 15, 2017

Primary completion

Feb 9, 2021

Study completion Feb 9, 2021

Sponsor

Lead sponsor
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
URC-CIC Paris Descartes Necker Cochin
First posted
Dec 22, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether somatostatin is more effective that octreotide in the prevention of post-pancreatectomy pancreatic fistula

Conditions

  • Pancreatic Surgery

Interventions

  • SomatostatinDrug

    Lyophilisate and solution for IV use (glass ampoule of lyophilisate + 1 ml glass ampoule of solvent) 6 mg per day Continuous intravenous infusion for 6,5 days

  • OctreotideDrug

    Solution for Subcutaneous use 100μg, every 8 hours Subcutaneous injection for 6,5 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ≥ grade B or C postoperative pancreatic fistula as defined by the International Study Group of Pancreatic Fistula (ISGPF) classificationTime frame: 90 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • La Pitié Salpêtrière Hospital

    Paris, France

  • Cochin Hospital

    Paris, Paris, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.